• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Acta oncologica

    Acta oncologica

    JournalISSN 0284-186XeISSN 1651-226X中科院 医学 3区

    年发文量

    研究主题

    论文(7498)

    排序
    1RET Fusion–positive Non-Small Cell Lung Cancer in Sweden: a Nationwide Registry Study
    Ella Äng Eklund,Hans Brunnström,Erik Lampa,Kerstin Gunnarsson,Anders Vikström,Johan Isaksson,Kristina Lamberg,Johan Botling,Henrik Fagman,Sama I. Sayin,Gunnar Wagenius,Levent M. Akyurek,

    Background: Rearranged during transfection (RET) fusion–positive non-small cell lung cancer (NSCLC) is a rare but clinically meaningful molecular subgroup. RET inhibitors have demonstrated marked clinical activity; however, real-world data on disease characteristics and outcomes before their widespread introduction remain limited. This study characterizes clinical features, treatment patterns, and survival outcomes of RET fusion–positive NSCLC in a nationwide Swedish cohort, with other driver subgroups as descriptive comparisons. Methods: Patients ≥18 years diagnosed with histologically confirmed NSCLC in 2018–2022, registered in the Swedish National Lung Cancer Registry and with next-generation sequencing results available, were included. Individuals were categorized by oncogenic driver status, including RET, ALK, BRAF, EGFR, KRAS, ROS1, or wild type. Progression-free survival (PFS) and overall survival (OS) from diagnosis were estimated using Kaplan–Meier methods and standardized Cox proportional hazards models adjusted for age, sex, performance status, smoking, stage, and histology. Results: A total of 68 patients had RET fusion–positive NSCLC. The RET cohort was characterized by younger age, a high proportion of never-smokers (59%), and predominantly adenocarcinoma histology (96%). Most had stage IV disease at diagnosis and the highest rate of liver metastases (56%). KIF5B–RET (71%) and CCDC6–RET (19%) were the most frequent fusion partners. Adjusted median OS was 28 months (95% confidence interval [CI]: 13–46) for RET, 39 months (95% CI: 29–52) for ALK, and 17–26 months for the other groups, with overlapping CIs. Conclusion: RET fusion–positive patients were typically younger never-smokers with adenocarcinoma and had encouraging OS, despite limited access to selective RET inhibitors during the study period.

    2026
    引用
    AI阅读
    加入学术空间
    2Clinical Factors Associated with Outcomes among Patients Receiving Second-Line Therapy for Advanced NSCLC
    Vasileios Karagiannis, Levi Byskata,Nelli-Sofia Nåhls, Eero Sihvo,Antti Jekunen,Mikael Johansson,Heidi Andersén
    2026
    引用
    AI阅读
    加入学术空间
    3Treatment Attrition and Outcomes of Myeloma Patients in Finland: a Real-World Study
    Mervi Putkonen, Katja Narhi,Johanna Vikkula,Riikka Mattila, Marika Waltari, Jonna Eeva,Anu Partanen

    Background and purpose: Relapses, need for further treatment lines and significant treatment attrition are typical for multiple myeloma (MM).This retrospective study investigates attrition and outcomes among MM patients in Finland. Patient, material and methods: Study included all adult MM patients (n = 1733) diagnosed and treated in four hospital districts in Finland in 2013-2022. Data were collected from hospital data lakes, Statistics Finland and Social Insurance Institution. Treatment attrition was defined as death before next treatment line. Results: By the end of follow-up 31% of patients without stem cell transplantation (non-SCT) had died before initiation of second line treatment (2L), compared with 5% of stem-cell transplant (SCT) patients. The factors associating with this early attrition in the non-SCT cohort were older age (over 75 years), higher comorbidity burden, International Staging System (ISS), and (R)-ISS scores (p < 0.001). Furthermore, non-SCT patients were more likely administered less intensive therapy during 1L (p < 0.001). During the first 6 months post diagnosis in the non-SCT cohort, the most common immediate cause of death was MM. Also, during later stages MM was responsible for 54% of deaths in the non-SCT and 68% in the SCT cohorts whereas infections were linked principally with early deaths before 2L treatment. Interpretation: This study highlights significant treatment attrition across disease course and also early mortality especially in the non-SCT cohort resulting primarily from progressive MM or infections. The findings underscore the need for more tolerable and effective anti-myeloma treatments in earlier course of the disease to enhance patient survival.

    2026
    引用
    AI阅读
    加入学术空间
    4Detection of Circulating Tumor HPV-DNA in Patients with HPV-positive Sinonasal and Nasopharyngeal Carcinoma
    Jakob Myllerup Jensen,Simone Kloch Bendtsen,Kathrine Kronberg Jakobsen,Katalin Kiss,Maria Rossing,Christian Gronhoj,Christian von Buchwald

    Background: Approximately 30% of sinonasal and nasopharyngeal carcinoma cases are HPV-associated, yet studies investigating circulating tumor HPV-DNA (ctHPV-DNA) among these patients are scarce. The aim of this study was to investigate the sensitivity of ctHPV-DNA in pretreatment blood samples from patients with HPV-positive (HPV+) sinonasal and nasopharyngeal carcinoma. Methods: Patients with a confirmed HPV+ sinonasal or nasopharyngeal carcinoma treated at the Department of Otorhinolaryngology, Head and Neck Surgery and Audiology at Rigshospitalet, Copenhagen, Denmark in the period 2017-2025 were included in this study. Blood samples were drawn in Streck tubes before treatment initiation and analysed for the presence of ctHPV-DNA by Droplet digital PCR (ddPCR). Results: Fifteen patients with primary HPV+ sinonasal or nasopharyngeal carcinoma were included. Except for two cases of HPV-related multiphenotypic carcinoma, all cases were squamous cell carcinoma. HPV16 was most prevalent and found in 6 patients (40%). HPV18 (n = 2), HPV33 (n = 1), HPV35 (n = 3), HPV45 (n = 1), and HPV56 (n = 2) were also represented. The sensitivity of detecting ctHPV-DNA in the pretreatment blood samples of the included patients was 80%. The level of ctHPV-DNA increased significantly with increasingT-category. Conclusion: ctHPV-DNA was detected in pretreatment blood samples in 80% of patients with HPV+ sinonasal and nasopharyngeal carcinoma. This supports further investigation of ctHPV-DNA as a biomarker for post-treatment surveillance in these patients.

    2026
    引用
    AI阅读
    加入学术空间
    5Continuous Intrathecal Therapy for Refractory Cancer Pain: A Systematic Review and Meta-Analysis Focusing on Partially Implanted Devices
    Mohammadhossein Radafshar, Maria Schelin,Elisabeth Bondesson, Sofia Löfvendahl, Eric Ahl, Sven Oredsson, Mikael Segerlantz

    Context: Conventional pain therapies sometimes fail in patients with severe neuropathic pain or bone metastases. Intrathecal therapy provides an alternative but is resource-intensive, technically demanding and costly. Objective: To compare the advantages and limitations of partially implanted devices (PIDs) versus conventional medical management or totally implanted devices (TIDs) in adults with cancer-related pain. Methods: A systematic literature review up to September 2024 was conducted, with an updated search performed in August 2026. Eligible studies included those on adults with refractory cancer pain receiving PID intrathecal therapy compared with conventional therapy, and comparative studies evaluating PIDs versus TIDs. Pain intensity was analysed using a meta-analysis; a synthesis without meta-analysis was used for other outcomes. Results: Of the 1,102 records, 15 were included, evaluating pain intensity, systemic opioid dose, quality of life (QoL), depression/anxiety, functional capacity and complications in PID-treated patients. A meta-analysis of pain intensity at 4 weeks showed statistically significant reduction with intrathecal therapy, which also reduced opioid use and improved QoL. Complication rates were lower than in conventional therapy. Investigations of depression/anxiety and functional capacity were limited, with inconsistent findings. Certainty of evidence was moderate for pain intensity and QoL; low for opioid dose, depression/anxiety and complications; and very low for functional capacity. Conclusions: Intrathecal therapy for refractory cancer pain with PIDs provides superior pain relief and improved QoL compared with the conventional therapy in patients with refractory cancer pain. Evidence for psychological and functional outcomes remains limited. Overall certainty of evidence is low to moderate, but findings support intrathecal therapy as a clinically meaningful option for selected patients.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 7498 篇论文

    高被引作者

    作者引用发文
    Jens Overgaard6313173
    Bengt Glimelius3747105
    Eero Pukkala359235
    Cai Grau307772
    Christoffer Johansen2686106
    Morten Høyer245168
    Susanne Oksbjerg Dalton228390
    Sophie D. Fosså215156
    Henric Blomgren213511
    Hr Withers21251

    高产作者

    作者引用发文
    Jens Overgaard6313173
    Christoffer Johansen2686106
    Bengt Glimelius3747105
    Susanne Oksbjerg Dalton228390
    Ludvig Muren202473
    Cai Grau307772
    Morten Høyer245168
    Sophie D. Fosså215156
    Per Pfeiffer140151
    Bent Laursen Ejlertsen164950

    相关期刊

    American journal of clinical oncology
    Clinical Oncology
    Japanese journal of clinical oncology
    Tumori
    Current Oncology Reports
    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
    ESMO Open
    Breast
    Strahlentherapie und Onkologie
    Asia-Pacific Journal Of Clinical Oncology